341 related articles for article (PubMed ID: 27226735)
1. Clinical use and applications of histone deacetylase inhibitors in multiple myeloma.
Tandon N; Ramakrishnan V; Kumar SK
Clin Pharmacol; 2016; 8():35-44. PubMed ID: 27226735
[TBL] [Abstract][Full Text] [Related]
2. Panobinostat: a novel pan-deacetylase inhibitor for the treatment of relapsed or relapsed and refractory multiple myeloma.
Richardson PG; Laubach JP; Lonial S; Moreau P; Yoon SS; Hungria VT; Dimopoulos MA; Beksac M; Alsina M; San-Miguel JF
Expert Rev Anticancer Ther; 2015; 15(7):737-48. PubMed ID: 26051506
[TBL] [Abstract][Full Text] [Related]
3. EMA Review of Panobinostat (Farydak) for the Treatment of Adult Patients with Relapsed and/or Refractory Multiple Myeloma.
Tzogani K; van Hennik P; Walsh I; De Graeff P; Folin A; Sjöberg J; Salmonson T; Bergh J; Laane E; Ludwig H; Gisselbrecht C; Pignatti F
Oncologist; 2018 May; 23(5):631-636. PubMed ID: 29192015
[TBL] [Abstract][Full Text] [Related]
4. Deacetylase inhibitors: an advance in myeloma therapy?
Laubach JP; San-Miguel JF; Hungria V; Hou J; Moreau P; Lonial S; Lee JH; Einsele H; Alsina M; Richardson PG
Expert Rev Hematol; 2017 Mar; 10(3):229-237. PubMed ID: 28076695
[TBL] [Abstract][Full Text] [Related]
5. Panobinostat From Bench to Bedside: Rethinking the Treatment Paradigm for Multiple Myeloma.
Berdeja JG; Laubach JP; Richter J; Stricker S; Spencer A; Richardson PG; Chari A
Clin Lymphoma Myeloma Leuk; 2021 Nov; 21(11):752-765. PubMed ID: 34340951
[TBL] [Abstract][Full Text] [Related]
6. Panobinostat for the treatment of multiple myeloma: the evidence to date.
Bailey H; Stenehjem DD; Sharma S
J Blood Med; 2015; 6():269-76. PubMed ID: 26504410
[TBL] [Abstract][Full Text] [Related]
7. Panobinostat for the treatment of relapsed or relapsed/refractory multiple myeloma: pharmacology and clinical outcomes.
Richardson PG; Harvey RD; Laubach JP; Moreau P; Lonial S; San-Miguel JF
Expert Rev Clin Pharmacol; 2016; 9(1):35-48. PubMed ID: 26503877
[TBL] [Abstract][Full Text] [Related]
8. Expression of histone deacetylase (HDAC) family members in bortezomib-refractory multiple myeloma and modulation by panobinostat.
Cheng T; Kiser K; Grasse L; Iles L; Bartholomeusz G; Samaniego F; Orlowski RZ; Chandra J
Cancer Drug Resist; 2021; 4(4):888-902. PubMed ID: 34888496
[TBL] [Abstract][Full Text] [Related]
9. Panobinostat, a pan-histone deacetylase inhibitor: rationale for and application to treatment of multiple myeloma.
Cheng T; Grasse L; Shah J; Chandra J
Drugs Today (Barc); 2015 Aug; 51(8):491-504. PubMed ID: 26380387
[TBL] [Abstract][Full Text] [Related]
10. Efficacy of Panobinostat for the Treatment of Multiple Myeloma.
Eleutherakis-Papaiakovou E; Kanellias N; Kastritis E; Gavriatopoulou M; Terpos E; Dimopoulos MA
J Oncol; 2020; 2020():7131802. PubMed ID: 32411240
[TBL] [Abstract][Full Text] [Related]
11. Histone deacetylase inhibitors in multiple myeloma: rationale and evidence for their use in combination therapy.
Kaufman JL; Fabre C; Lonial S; Richardson PG
Clin Lymphoma Myeloma Leuk; 2013 Aug; 13(4):370-6. PubMed ID: 23787122
[TBL] [Abstract][Full Text] [Related]
12. Histone deacetylase inhibitor panobinostat induces calcineurin degradation in multiple myeloma.
Imai Y; Ohta E; Takeda S; Sunamura S; Ishibashi M; Tamura H; Wang YH; Deguchi A; Tanaka J; Maru Y; Motoji T
JCI Insight; 2016 Apr; 1(5):e85061. PubMed ID: 27699258
[TBL] [Abstract][Full Text] [Related]
13. Panobinostat for the treatment of multiple myeloma.
Neri P; Bahlis NJ; Lonial S
Expert Opin Investig Drugs; 2012 May; 21(5):733-47. PubMed ID: 22404247
[TBL] [Abstract][Full Text] [Related]
14. Incidence and management of adverse events associated with panobinostat in the treatment of relapsed/refractory multiple myeloma.
Moore DC; Arnall JR; Harvey RD
J Oncol Pharm Pract; 2019 Apr; 25(3):613-622. PubMed ID: 30060709
[TBL] [Abstract][Full Text] [Related]
15. [Role of HDAC isoforms and development of treatment of multiple myeloma using isoform-specific HDAC inhibitors].
Harada T
Rinsho Ketsueki; 2019; 60(9):1265-1274. PubMed ID: 31597852
[TBL] [Abstract][Full Text] [Related]
16. Efficacy and tolerability of the histone deacetylase inhibitor panobinostat in clinical practice.
Baertsch MA; Hillengass J; Blocka J; Schönland S; Hegenbart U; Goldschmidt H; Raab MS
Hematol Oncol; 2018 Feb; 36(1):210-216. PubMed ID: 28685863
[TBL] [Abstract][Full Text] [Related]
17. Novel Proteasome Inhibitors and Histone Deacetylase Inhibitors: Progress in Myeloma Therapeutics.
Chhabra S
Pharmaceuticals (Basel); 2017 Apr; 10(2):. PubMed ID: 28398261
[TBL] [Abstract][Full Text] [Related]
18. Outcomes with panobinostat in heavily pretreated multiple myeloma patients.
Pan D; Mouhieddine TH; Upadhyay R; Casasanta N; Lee A; Zubizarreta N; Moshier E; Richter J
Semin Oncol; 2023; 50(1-2):40-48. PubMed ID: 37005144
[TBL] [Abstract][Full Text] [Related]
19. Bortezomib, thalidomide, dexamethasone, and panobinostat for patients with relapsed multiple myeloma (MUK-six): a multicentre, open-label, phase 1/2 trial.
Popat R; Brown SR; Flanagan L; Hall A; Gregory W; Kishore B; Streetly M; Oakervee H; Yong K; Cook G; Low E; Cavenagh J;
Lancet Haematol; 2016 Dec; 3(12):e572-e580. PubMed ID: 27843120
[TBL] [Abstract][Full Text] [Related]
20. The Role of Panobinostat Plus Bortezomib and Dexamethasone in Treating Relapsed or Relapsed and Refractory Multiple Myeloma: A European Perspective.
San-Miguel JF; Einsele H; Moreau P
Adv Ther; 2016 Nov; 33(11):1896-1920. PubMed ID: 27677481
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
